Le Lézard
Classified in: Health, Science and technology, Business

Rapid Micro Biosystems Announces Appointment of Melinda Litherland to Board of Directors

LOWELL, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) ("Rapid Micro"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to welcome Melinda Litherland to its board of directors.

Appointed to the board in June 2021, Litherland is a former partner and specialist in the Technology and Life Sciences industry groups of Deloitte & Touche LLP. She has more than 30 years of audit experience in service to companies ranging from emerging venture-backed clients to large multinationals. Litherland is a certified public accountant with a Bachelor of Arts degree in Economics from Rice University and a Master of Accounting degree from the Rice University Jones Graduate School of Business. She also serves on the board of directors at Bio-Rad Laboratories, Inc., chairing the audit committee.

"We are thrilled to welcome a board member with Melinda's extensive financial and life sciences background to Rapid Micro Biosystems," said President and CEO Robert Spignesi. "As an independent director, she brings a wealth of experience with the complex accounting and business matters that Rapid Micro Biosystems will face as we pursue our vision of becoming the trusted standard in the global microbial quality control (MQC) marketplace."

"I am excited to join the board at Rapid Micro Biosystems at an energizing time in the company's growth," Litherland said. "As the company pursues its vision, I welcome the opportunity to share my experience."

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct® platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct® platform brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the company on Twitter at @rapidmicrobio or on LinkedIn.




These press releases may also interest you

at 04:05
Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin) today announced the publication of new data highlighting the sustained benefits of treatment with CRYSVITA® (burosumab) in adults with X-linked hypophosphataemia (XLH), a rare genetic metabolic bone...

at 03:55
International science publisher SelectScience has been praised by a representative of HM Queen Elizabeth II for its work during the pandemic. The warm words came from HM Lord-Lieutenant of Somerset Annie Maw, as she presented the SelectScience team...

at 03:00
Zentiva announces the launch of the Zentiva Academy, its new digital learning and development platform aimed at providing its employees with the best opportunities for their professional and personal growth. The program gathers a range of assets...

at 03:00
U.S. Dermatology Partners will sponsor and staff a skin cancer screening at the 11th Annual Swim Across America Dallas Open Water Swim on September 25th. Swim Across America Inc., is a nonprofit dedicated to raising money and awareness for cancer...

at 02:41
Akeso, Inc. (the Company, 9926.HK) announces that the National Medical Products Administration (the NMPA) of China has officially accepted the new drug application for the world's first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody, research...

at 02:27
Colzyx AB (Colzyx) and the European Innovation Council Fund (EIC Fund) have signed the agreement for the first investment of EUR 1m in Colzyx by the EIC Fund. This investment is the result of the EUR 5.5 million in financial support from the Horizon...

News published on 3 august 2021 at 16:30 and distributed by: